Skip to content
April 23, 2024

Equity.Guru

Investment information for the new generation

Search

tumors

Feliz Navidea $29.79M Market Capitalization Navidea Biopharmaceuticals Inc. (NAVB.NYSE) announced today that it has received regulatory approval in India for its Lymphoaim, also referred to as Lymphoseek in the…
Protagonist Therapeutics (PTGX.Q) announced the receipt of verbal communication from the U.S. Food and Drug Administration (FDA) that the Company’s clinical studies for rusfertide have been placed on a…